Clinical Trial

NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC

Name: NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC — clinical trial record (NCT06966583)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NMN

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a phase I, single center (West China Hospital, Sichuan University) study aimed at investigating the safety and efficacy of NMN supplements combined with chemotherapy and radiation therapy for second-line and above treatment of advanced NSCLC.

Trial Details

NCT Number	NCT06966583
Lead Sponsor	Sichuan University
Conditions	Solid Tumor, Non Small Cell Lung Cancer
Enrollment	20 participants
Start Date	2025-05-01
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-12